Research programme: anti-metastasis immunoconjugates - Oncomatrix/University of Stuttgart

Drug Profile

Research programme: anti-metastasis immunoconjugates - Oncomatrix/University of Stuttgart

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OncoMatrix
  • Class Immunoconjugates
  • Mechanism of Action Extracellular matrix protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer metastases

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer-metastases in Spain (Parenteral)
  • 11 Dec 2012 OncoMatrix and the University of Stuttgart collaborate to develop immunoconjugates for Cancer metastases
  • 31 Dec 2000 Early research in Cancer metastases in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top